Enanta Pharmaceuticals, Inc.(ENTA)

Sector:

Healthcare

Description:

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Current Price

$25.93

RSI

59.11

Market Capitalization:

1.3B

Beta:

0.6

Volume:

143,131

Analyst Target Price:

$ 87.44

Economiic Fair Price:


February 14, 2023
November 23, 2022
Q4
N/A
N/A
N/A
N/A
N/A
-4.989
-108.40 %
4.593
-0.241

-10.92 %
-37.43 %
-108.13 %
-13.82 %
21.14 %
19.39 %

$ 86.2M
-11.24 %
$ 97.1M
-20.74 %
$ 122.5M
-40.31 %
$ 205.2M
-0.69 %
$ 206.6M
100.97 %
$ 102.8M

$ -86.9M
-22.84 %
$ -70.7M
-1353.69 %
$ 5.6M
-91.45 %
$ 66M
151.54 %
$ 26.2M
-47.68 %
$ 50.1M

$ -122.2M
-13.58 %
$ -107.6M
-207.20 %
$ -35M
-176.87 %
$ 45.6M
-51.08 %
$ 93.1M
245.57 %
$ 26.9M

News

Press Releases

Notable Dates